220 related articles for article (PubMed ID: 18062731)
41. Effect of Carving in Pharmacy Benefits on Utilization and Costs.
Parekh N; Papa S; Drnach A; Spiegel L; Huang Y; Manolis C; Good CB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1317-1324. PubMed ID: 32996397
[TBL] [Abstract][Full Text] [Related]
42. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
Brouwer E; Yeung K; Barthold D; Hansen R
J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
[No Abstract] [Full Text] [Related]
43. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data.
Carroll CA; Fairman KA; Lage MJ
BMC Health Serv Res; 2014 Jul; 14():286. PubMed ID: 24986083
[TBL] [Abstract][Full Text] [Related]
44. A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
San-Juan-Rodriguez A; Gellad WF; Shrank WH; Good CB; Hernandez I
J Manag Care Spec Pharm; 2021 May; 27(5):565-573. PubMed ID: 33908276
[No Abstract] [Full Text] [Related]
45. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
Curtiss FR
J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
[No Abstract] [Full Text] [Related]
46. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
Valluri S; Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL
BMC Health Serv Res; 2007 Jul; 7():122. PubMed ID: 17663768
[TBL] [Abstract][Full Text] [Related]
47. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
Bian B; Kelton CM; Guo JJ; Wigle PR
J Manag Care Pharm; 2010; 16(9):671-9. PubMed ID: 21067253
[TBL] [Abstract][Full Text] [Related]
48. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
Yokoyama K; Yang W; Preblick R; Frech-Tamas F
J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
[TBL] [Abstract][Full Text] [Related]
49. Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.
Martin C; Odell K; Cappelleri JC; Bancroft T; Halpern R; Sadosky A
J Manag Care Spec Pharm; 2016 Feb; 22(2):132-44. PubMed ID: 27015252
[TBL] [Abstract][Full Text] [Related]
50. Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims.
Zhang J; Haynes K; Mendelsohn AB; Marshall J; Barr CE; McDermott C; Brown J; Kline A; Kenney J; King KJ; Holmes C; Yeung K; Barron J; Yun H; Lockhart CM
Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):778-785. PubMed ID: 31802568
[TBL] [Abstract][Full Text] [Related]
51. Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018.
Elsisi Z; Hincapie AL; Guo JJ
Am Health Drug Benefits; 2020 May; 13(2):74-84. PubMed ID: 32724502
[TBL] [Abstract][Full Text] [Related]
52. Effects of a consumer driven health plan on pharmaceutical spending and utilization.
Parente ST; Feldman R; Chen S
Health Serv Res; 2008 Oct; 43(5 Pt 1):1542-56. PubMed ID: 18479407
[TBL] [Abstract][Full Text] [Related]
53. Reduced medical spending associated with integrated pharmacy benefits.
Lucas E; Liu M; Ouyang J; Vicidomina B; Ford M; Keller BP; Nigam S
Am J Manag Care; 2021 Jul; 27(7):e242-e247. PubMed ID: 34314125
[TBL] [Abstract][Full Text] [Related]
54. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
55. Prescription drug costs and the generic dispensing ratio.
Liberman JN; Roebuck MC
J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
[TBL] [Abstract][Full Text] [Related]
56. Twelve-month drug cost savings related to use of an electronic prescribing system with integrated decision support in primary care.
McMullin ST; Lonergan TP; Rynearson CS
J Manag Care Pharm; 2005 May; 11(4):322-32. PubMed ID: 15871643
[TBL] [Abstract][Full Text] [Related]
57. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
58. Increasing use of disease modifying drugs for MS in Canada.
Rotstein DL; Mamdani M; O'Connor PW
Can J Neurol Sci; 2010 May; 37(3):383-8. PubMed ID: 20481274
[TBL] [Abstract][Full Text] [Related]
59. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
60. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
